non-nmda

Aptiganel (CNS-1102) is a non-competitive NMDA antagonist, a peptide that may be used to study acute ischemic stroke.

Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.

Flupirtine maleate (Katadolon maleate), a centrally acting non-opioid analgesia, is the salt form of Flupirtine. It is an NMDA receptor antagonist , and also a specific neuronal potassium channel opener.

L-Phenylalanine (3-Phenyl-L-alanine) is an essential amino acid and the precursor of the amino acid tyrosine, acts as an antagonist at α2δ calcium channels.

glycine (2-Aminoacetic acid) is a non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

Eliprodil (SL-820715)(SL-820715), a non-competitive NR2B-NMDA receptor antagonist(IC50: 1 uM), less effective for NR2A- and NR2C-containing receptors(IC50> 100 uM). It has been used in trials studying the treatment of Parkinson Disease and Movement Disorders.

DNQX disodium salt is a water-soluble form of selective antagonist of non-NMDA receptor

4-PPBP maleate is a potent σ1 receptor (ligand) agonist and a selective, non-competitive NR1a 2B NMDA receptor antagonist in the context of Xenopus oocytes expression, with neuroprotective properties.

QNZ46 is a non-competitive antagonist of NMDA receptors, selectively targeting NR2C NR2D subunits.

N20C hydrochloride (2-((3,3-diphenylpropyl)amino)acetamide hydrochloride) is a non-competitive NMDA receptor open-channel blocker.

Gavestinel (GV 150526) is a non-competitive NMDA receptor antagonist that is potent, selective and orally active.Gavestinel binds to the glycine site of the NMDA receptor with a binding affinity (pKi value) of 8.5.Gavestinel is used in acute ischaemic stroke studies.

Flupirtine HCl is the salt form of Flupirtine, also known as W-2964, an aminopyridine that functions as a centrally acting non-opioid analgesic. It first became available in Europe in 1984, and is sold mainly under the names Katadolon, Trancolong, Awegal, Efiret, Trancopal Dolo, and Metanor. Like nefopam, it is unique among analgesics in that it is a non-opioid, non-NSAID, non-steroidal centrally acting analgesic. Flupirtine is a selective neuronal potassium channel opener that also has NMDA receptor antagonist and GABAA receptor modulatory properties.

SR142948A is a selective and reversible non-peptide neurotensin receptor antagonist capable of blocking hypothermia and analgesic effects induced by intracerebroventricular injection of NT, and capable of concentration- and volume-dependent blockade of NMDA-induced dopamine release.

DNQX (FG 9041) is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors, respectively)

Aptiganel hydrochloride（Cerestat） is the salt form of Aptiganel.Aptiganel is a non-competitive NMDA antagonist with neuroprotective effects used in the treatment of stroke and focal cerebral ischemia.

CNQX (FG9065) is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.3 and 1.5 μM for AMPA and kainate receptors, respectively)

1. Rhynchophylline (Mitrinermine) can protect against ischemic damage, probably via regulating the Akt mTOR pathway. 2. Rhynchophylline can protect against glutamate-induced neuronal death, can inhibit MA impairment in cultured neurons in vitro. 3. Rhynchophylline and isorhynchophylline have a non-competitive antagonistic effect on the NMDA-type ionotropic glutamate receptors, suggest that these alkaloids exert their protective action against ischemia-induced neuronal damage by preventing NMDA, muscarinic M1, and 5-HT2 receptors-mediated neurotoxicity during ischemia.

inhibits [3H]-homoquinolinic acid binding to non-NMDA sensitive sites

HSD17B13-IN-7 (compound 1) is a fluorophenol-containing compound that acts as a potent HSD17B13 inhibitor, with IC₅₀ values of 0.18 μM and 0.25 μM using β-estradiol and Leukotriene B4 as substrates, respectively. Additionally, HSD17B13-IN-7 serves as a potent antagonist of the N-methyl-D-aspartate (NMDA) NR2B receptor and shows potential for research on non-alcoholic fatty liver disease [1].

GYKI-52466 is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >50 μM for AMPA-, kainate- and NMDA-induced responses, respectively) used as a Skeletal muscle relaxant, orally active anticonvulsant, neuroprotective and

NMDA receptor antagonist 5 (Compound 10e), a potent and non-toxic agent with brain permeability, is significant for studying neurological disorders [1].

CNQX disodium is a competitive non-NMDA receptor antagonist and competitive AMPA kainate receptor antagonist in neuronal cultures.

(-)-Dizocilpine maleate ((-)-MK 801 (Maleate)) is a potent, selective, and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes.

N-Methyl-D-aspartate (NMDA) receptors are Ca2+ permeable ligand-gated channels of the central nervous system that are activated after binding of the co-agonists glutamate and glycine. CAY10608 is a propanolamine that potently, selectively, and non-competitively antagonizes the NR2B subunit of NMDA receptors (IC50 = 50 nM). It does not inhibit NR1, NR2A, NR2C, and NR2D subunits and has no significant effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropioinic acid (AMPA) or kainate receptors. CAY10608 is neuroprotective, since it prevents NMDA-triggered release of lactate dehydrogenase from cultured cortical neurons. Also, CAY10608, when administered intraperitoneally, reduces brain infarct volume resulting from transient ischemia via carotid artery occlusion.